When life threatening conditions are being studied eg cancer, serious infections mild AEs or SAEs would not eliminated a drug from being approved as a treatment as long as it successfully prolongs a reasonable quality of life.
As I mentioned in my previous post I have concerns about Remdesivir because of the studies performed, on my review , did not clearly outline side effects which may rule out its use in recently infected patients with no severe pulmonary or other side effects.
On the other hand if Brilacidin 's clinical trial confirms its effectiveness in treating Covid19, I could see it being given early in the course of the disease to reduce the pulmonary complications especially in patients with higher risk factors eg age, CVD, DM etc.
Hopefully we will know about Brilacidin's Covid19 human respiratory epithelial cells study soon.
GLTA,Farrell
As I mentioned in my previous post I have concerns about Remdesivir because of the studies performed, on my review , did not clearly outline side effects which may rule out its use in recently infected patients with no severe pulmonary or other side effects.
On the other hand if Brilacidin 's clinical trial confirms its effectiveness in treating Covid19, I could see it being given early in the course of the disease to reduce the pulmonary complications especially in patients with higher risk factors eg age, CVD, DM etc.
Hopefully we will know about Brilacidin's Covid19 human respiratory epithelial cells study soon.
GLTA,Farrell
12
